Trebicka, JonelGu, WenyiIbáñez-Samaniego, LuisHernández-Gea, VirginiaPitarch, CarlaGarcia, ElisabetProcopet, BogdanGiráldez, ÁlvaroAmitrano, LucioVillanueva, CandidThabut, DominiqueSilva-Junior, GilbertoMartinez, JavierGenescà, JoanBureau, CristopheLlop, ElbaLaleman, WimPalazon, Jose MariaCastellote, JoseRodrigues, SusanagGluud, LiselotteFerreira, Carlos NoronhaBarcelo, RafaelCañete, NuriaRodríguez, ManuelFerlitsch, ArnulfMundi, Jose LuisGronbaek, HenningHernández-Guerra, ManuelSassatelli, RomanoDell'Era, AlessandraSenzolo, MarcoAbraldes, Juan GRomero-Gómez, ManuelZipprich, AlexanderCasas, MeritxellMasnou, HelenaPrimignani, MassimoWeiss, EmmanuelCatalina, Maria-VegaErasmus, Hans-PeterUschner, Frank ErhardSchulz, MartinBrol, Maximilian JPraktiknjo, MichaelChang, JohannesKrag, AleksanderNevens, FrederikCalleja, Jose LuisRobic, Marie AngèleConejo, IreneAlbillos, AgustinRudler, MarikaAlvarado, EdilmarGuardascione, Maria AnnaTantau, MarcelBosch, JaimeTorres, FerranPavesi, MarcoGarcia-Pagán, Juan CarlosJansen, ChristianBañares, RafaelInternational Variceal Bleeding Observational Study Group and Baveno Cooperation2023-02-082023-02-082020-04-24http://hdl.handle.net/10668/15445The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date. A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality. At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality in patients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB. Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Acute variceal bleedingAcute-on-chronic liver failureCirrhosisRebleedingAcute-On-Chronic Liver FailureEarly Medical InterventionEsophageal and Gastric VaricesEuropeFemaleGastrointestinal HemorrhageHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedPortasystemic Shunt, Transjugular IntrahepaticPrevalencePrognosisRecurrenceRisk AdjustmentRisk Assessmentresearch article32339602open access10.1016/j.jhep.2020.04.0241600-0641http://www.journal-of-hepatology.eu/article/S0168827820302361/pdf